Cover Image
市場調查報告書

類澱粉蛋白沉積症:開發中產品分析

Amyloidosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192465
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
Back to Top
類澱粉蛋白沉積症:開發中產品分析 Amyloidosis - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 160 Pages
簡介

以類澱粉蛋白沉積症知名的疾病群,是由於Amyloid蛋白質在體內組織異常積蓄所造成。由於會影響到內臟形狀及功能,甚至也可能最後造成臟器功能衰竭。因素有被稱為L鎖的異常蛋白質錯誤折疊,持續下去後積蓄於體內。也可能是透析結果造成。其常見的症狀有倦怠感、胸痛、腫脹、呼吸障礙等。治療方法包含有移植、給藥(利尿劑、化療藥)等。

本報告提供類澱粉蛋白沉積症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

類澱粉蛋白沉積症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • ProteoTech, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALN-TTRsc02
  • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
  • carfilzomib
  • CLR-01
  • eprodisate disodium
  • GSK-2315698 + GSK-2398852
  • GSK-2398852
  • ixazomib citrate
  • LUNAR-101
  • LUNAR-102
  • Monoclonal Antibody for Amyloidosis
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
  • NEOD-001
  • NPT-005
  • patisiran
  • pomalidomide
  • PTI-110
  • revusiran
  • Small Molecules for AL Amyloidosis
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
  • tafamidis meglumine
  • tolcapone

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9004IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H1 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 4 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Amyloidosis - Overview
  • Amyloidosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Amyloidosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Amyloidosis - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Amgen Inc
    • Arcturus Therapeutics Inc
    • Bsim2
    • Celgene Corp
    • GlaxoSmithKline Plc
    • Ionis Pharmaceuticals Inc
    • Johnson & Johnson
    • Millennium Pharmaceuticals Inc
    • Neurimmune Holding AG
    • Novartis AG
    • Oncopeptides AB
    • Pfizer Inc
    • Proclara Biosciences Inc
    • Prothena Corp Plc
    • R Pharm
    • Regeneron Pharmaceuticals Inc
    • SOM Biotech SL
    • Spectrum Pharmaceuticals Inc
  • Amyloidosis - Drug Profiles
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-TTRsc02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAEL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daratumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezamizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezamizumab + GSK-2315698 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxycycline hyclate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2315698 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3039294 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUNAR-TTR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melphalan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melphalan flufenamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEOD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-289 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tolcapone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Amyloidosis - Dormant Projects
  • Amyloidosis - Discontinued Products
  • Amyloidosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 04, 2017: Fortress Biotech Forms New Subsidiary, Caelum Biosciences to Develop Novel Treatment for AL Amyloidosis
      • Dec 16, 2016: Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
      • Nov 07, 2016: VYNDAQEL (tafamidis) Receives Approval in Brazil by ANVISA for the Treatment of Transthyretin Familial Amyloid Polyneuropathy
      • Nov 03, 2016: Data for Prothena NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting
      • Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
      • Sep 23, 2016: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
      • Aug 08, 2016: Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease
      • Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
      • Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
      • Jul 05, 2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
      • Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis
      • Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis
      • Jun 21, 2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
      • Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Amyloidosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
  • Amyloidosis - Pipeline by Amgen Inc, H1 2017
  • Amyloidosis - Pipeline by Arcturus Therapeutics Inc, H1 2017
  • Amyloidosis - Pipeline by Bsim2, H1 2017
  • Amyloidosis - Pipeline by Celgene Corp, H1 2017
  • Amyloidosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Amyloidosis - Pipeline by Johnson & Johnson, H1 2017
  • Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2017
  • Amyloidosis - Pipeline by Novartis AG, H1 2017
  • Amyloidosis - Pipeline by Oncopeptides AB, H1 2017
  • Amyloidosis - Pipeline by Pfizer Inc, H1 2017
  • Amyloidosis - Pipeline by Proclara Biosciences Inc, H1 2017
  • Amyloidosis - Pipeline by Prothena Corp Plc, H1 2017
  • Amyloidosis - Pipeline by R Pharm, H1 2017
  • Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Amyloidosis - Pipeline by SOM Biotech SL, H1 2017
  • Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Amyloidosis - Dormant Projects, H1 2017
  • Amyloidosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Amyloidosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top